- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Clinical translation

Our research aims to improve health outcomes. Clinical translation converts basic research discoveries into better ways to prevent, diagnose and treat disease. We are facilitating linkages between clinicians and laboratory researchers, and supporting clinical research.
Our clinical translation
We are committed to harnessing the talent of our researchers to deliver real healthcare improvements. Our Clinical Translation Centre fosters linkages between our laboratory researchers and clinicians.
Key aspects of our clinical translation program are:
- Supporting the involvement of clinician-scientists in our research programs.
- Enabling our researchers’ involvement in the development, delivery and evaluation of clinical trials.
- Facilitating the collection and analysis of human samples for approved research.
More than 100 current clinical trials are based on discoveries made at the Institute.
What is clinical translation?
Clinical translation is research that leads to better understanding of disease, and/or development of new diagnostic tests or treatments.
Clinical translation may involve:
- Measuring the impact of a new strategy to prevent, treat or diagnose a disease in humans, using a clinical trial.
- Analysing human samples, such as those taken from people with a certain disease.
- Matching the genetic information (genome sequence) of a patient with features of their disease.
How do laboratory discoveries reach the clinic?
Many discoveries that have benefited the health of the community arose from basic laboratory research. Understanding how molecules, cells and tissues normally function gives insights into what goes wrong in disease.
Discovering how a disease develops can lead to new ways to prevent, treat and diagnose that disease. These are collectively called ‘interventions’.
Preclinical studies are used to test a proposed intervention in the laboratory, using patient samples or models that are similar to the diseased cells.
Clinical trials enable testing of the new intervention in people who have volunteered for the trial. Most clinical trials are conducted in stages:
Phase I: Tests the safety of the intervention in a small number of people, and whether the intervention works as intended.
Phase II: Determines how well the intervention can work.
Phase III: Uses a larger group of people to measure the overall benefits of the new intervention, comparing it with no intervention, or other existing interventions.
If an intervention shows success through all the stages of a clinical trial, it may then need government approval before it is available to the public. In Australia, the Therapeutic Goods Administration assesses the outcomes of clinical trials to approve new treatments, diagnostic tests or other interventions.
It often takes years or decades for a laboratory discovery to be translated into an improvement in healthcare. The successful outcomes of clinical trials requires:
- The intervention to be effective and improve health outcomes.
- Funding for the significant costs of conducting clinical trials. This is why many clinical trials are conducted with investment from pharmaceutical companies.
Who can participate in research?
Research participants are integral to clinical translation. These people must be:
- Willing to participate and able to attend a study or trial location.
- Fully informed about what their participation involves including any foreseeable risks.
- Aware of their rights to withdraw from the study.
- Eligible to participate in the study by meeting specified criteria, such as clinical diagnosis, medical history, or age.
Information about current clinical trials is available from:
- Your healthcare provider.
- Australian New Zealand Clinical Trials Registry.
- ClinicalTrials.gov, maintained by the US National Institutes of Health.
By joining the Volunteer Blood Donor Registry you can contribute to medical research aimed at preventing, treating and curing disease.
Governance of clinical translation
All research at the Walter and Eliza Hall Institute that involves people is overseen by our Human Research Ethics Committee. The committee’s operation is approved by the National Health and Medical Research Council (NHMRC), and conforms to the NHMRC National Statement on Ethical Conduct in Research Involving Humans (2007).
Translational research at the Institute is facilitated by our Clinical Translation Standing Committee. This committee:
- Provides advice on translational and clinical research.
- Assists with the operation of the Clinical Translation Centre.
- Contributes to the recruitment and support of medically qualified researchers at the Institute.
Consumer involvement
Wherever possible, we aim to involve ‘consumers’ in our research. A consumer is a person who has been affected by a disease. They may have:
- Suffered the disease themselves or
- Cared for a family member or friend with the disease.
The conduct of medical research can be improved by considering consumers’ personal and professional experiences. This can:
- Strengthen medical research design.
- Improve the communication of results to the community.
- Ensure research addresses questions that are important for consumers.
- Educate researchers to understand their disease fully from a consumer point of view.
Our Consumer Advisory Panel has been established to better connect our research with community experiences of disease and consumer expectations.
Researchers:
Clinician scientists Associate Professor Jeanne Tie and Associate Professor Sumitra Ananda are leading trials of a blood test to guide cancer treatment after surgery.
Professor Andrew Roberts and collaborators have shown that patients with an advanced form of leukaemia can achieve complete remission with a novel tablet treatment.